You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a novel system combining cognitive assessment with PASCALL FDA-cleared intraoperative anesthesia EEG brain monitor to prevent postoperative neurocognitive disorders in aging patients

    SBC: PASCALL Systems, Incorporated            Topic: NIA

    Each day, more than 100,000 patients undergo general anesthesia in the United States. The current practice of general anesthesia is prone to over-sedating patients, either due to the lack of brain monitoring or using brain monitors with inaccurate indices. Over-sedation (at 28% incidence) contributes to perioperative neurocognitive disorders (PNDs) in elderly population (≥65yrs). The cost of PND ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine

    SBC: NeuImmune, Inc.            Topic: NIAID

    ABSTRACTGlobally, more than 71 million people are infected with Hepatitis C virus (HCV), with 1-2 million new infections occurring each year. This major health concern necessitates the development of an effective vaccine. Since HCV rapidly accumulates mutations, vaccines must elicit the production of broadly neutralizing antibodies (bnAbs) in a reproducible fashion. The viral envelope E1E2 glycopr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Water-based liquid embolic agent for the treatment of vascular rich tumors

    SBC: AQUATEX MEDICAL INC            Topic: 102

    AquaTeX Medical is developing a novel liquid embolic material (LEM) - Aqua Embolic System (AES) - to improve cancer treatment. AES is designed to occlude feeding vessels of hypervascular tumors with superior efficacy and excellent biocompatibility as compared to other trans-arterial embolization (TAE) materials.TAE is a catheter-based treatment to treat hypervascular tumors. Embolic materials are ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. AIVIS: Next Generation Vigilant Information Seeking Artificial Intelligence-based Clinical Decision Support for Sepsis

    SBC: HEALCISIO INC            Topic: NIAID

    Abstract Sepsis, a heterogeneous syndrome characterized by whole-body inflammation caused by the body's response to an infection, is the most expensive and deadly condition treated in hospitals, with over 270,000 cases of sepsis-related deaths in the U.S. alone. The cornerstones of optimal sepsis care are early recognition accompanied by appropriate antimicrobial therapy, and use of evidence-based ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose control reduces microvascular complications and adverse cardiovascular events. Insulin therapy is essential for such patients, but has shortcomings: a) only 1 in 3 patients achieve targeted glucose control ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives of the endogenous glucoregulatory hormone, glucagon-like peptide-1 (GLP1) are in clinical use for the treatment of T2D but are also of great interest as an emerging treatment of obesity. Another closel ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. AAV-AIBP Therapy for Alzheimer's Disease

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIA

    PROJECT SUMMARY Therapy for Alzheimer’s disease and related dementias (AD/ADRD), slow-progressing neurodegenerative diseases, remains elusive. Therapeutic approaches focusing on beta amyloid (Aβ) removal from the brain or on targeting genes for which strong associations between their polymorphism and AD/ADRD are established, have had a mixed record of success. We propose a novel strategy to rev ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis

    SBC: Briopryme Biologics, Inc.            Topic: 102

    PROJECT SUMMARY Radiation therapy is a widely used treatment modality for pelvic malignancies such as prostate and cervical cancer; however, the high doses needed to confer therapeutic benefit often inflict significant damage on the normal issue in and surrounding the radiation field. The most frequent complication of pelvic radiation is proctitis, which nearly all patients experience acutely and ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Audiom: Developing an Indoor Non-Visual Mapping System

    SBC: XR NAVIGATION INC            Topic: NEI

    Project Abstract Indoor navigation for blind and visually impaired individuals (BVIs) within unfamiliar locations is typically an incredibly anxiety-provoking and stressful experience for numerous reasons, e.g., inaccessible signage including directories and venue maps, and if braille signs do exist, they are difficult to find, lack directional information, and are useless to the BVIs who do not r ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Developing of a computer-based multimodal mind and body approach for mild cognitive decline

    SBC: BRAIN THRIVE TECHNOLOGY LLC            Topic: NIA

    Summary Mild cognitive impairment (MCI) represents an intermediate state between normal aging and the diagnosis of clinically probable very early Alzheimer's disease (AD). Since MCI manifests before the onset of AD, it may be the optimal stage in which to intervene with preventative therapies for AD and age-related dementia before progressive neurological loss and irreversible cognitive impairment ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government